Evidence map›Paper›PMID 38780680›Full record

ArticleJournal of gastrointestinal cancer2024

Repeat Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors: A NET Center of Excellence Experience.

Udhayvir S Grewal, Bradley T Loeffler, Alexander Paschke, Joseph S Dillon, Chandrikha Chandrasekharan

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Long-term toxicity of tandem radioligand therapy using [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. The University of Iowa Neuroendocrine Tumor Clinic.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Udhayvir S GrewalDivision of Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
Bradley T LoefflerUniversity of Iowa Holden Comprehensive Cancer Center, Iowa City, IA, USA.
Alexander PaschkeDepartment of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
Joseph S DillonUniversity of Iowa Holden Comprehensive Cancer Center, Iowa City, IA, USA.
Chandrikha ChandrasekharanDivision of Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. chandrikha-chandrasekharan@uiowa.edu.

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0M
6 · The paper itself

Abstract

introductionThe available data for the safety and efficacy of repeat peptide receptor radionuclide therapy (PRRT) are almost exclusively from European centers. We present an updated experience with repeat PRRT in a cohort of US patients with neuroendocrine tumors (NETs) at our NET center of excellence.

methodsWe used our single-center longitudinal NET registry to identify patients who had been previously treated with at least one dose of PRRT (PRRT 1, either

resultsA total of 11 patients were included in the analysis. 45.5% (5/11) of patients received

conclusionWe show that repeat PRRT may benefit select patients and have an acceptable safety profile. In our cohort, PFS was significantly lower after PRRT2 as compared to PRRT1.

Indexed as

Neuroendocrine TumorsOctreotideAdultAgedFemaleHumansMaleMiddle AgedOrganometallic CompoundsRadiopharmaceuticalsReceptors, PeptideRetrospective Studieslutetium Lu 177 dotatateOctreotideOrganometallic CompoundsRadiopharmaceuticalsReceptors, PeptideNeuroendocrine neoplasmsNeuroendocrine tumorsPeptide receptor radionuclide therapy

Identifiers

PMID38780680

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.